KNIH-2023 Grant Program(TB)_RFP Second Announcement
Update 31.10.2023
KNIH(Korea National Institute of Health)
- 2023 Grant Program
Official announcement on international collaborative research
for tuberculosis
(Sponsored by Korea National Institute of Health, KDCA)
1. Preface
Tuberculosis (TB) is a preventable and curable disease, but remains a public threat worldwide. In Global TB Report, World Health Organization(WHO) estimated 10.6 million people getting ill by tuberculosis infection in 2021. To achieve the global goal of END-TB, it is critical to develop the effective drug and find reliable biomarkers are central strategy to control TB. The Korea National Institute of Health (KNIH) has spared no effort to promote research activity in tuberculosis field and believes that multi national collaboration guarantees the prevail in battle against tuberculosis. To facilitate the international collaboration on clinical research for tuberculosis, Division of Bacterial Disease Research of Korea National Institute of Infectious Disease (KNIID) is accepting proposals to provide fund research project conducted by institutes of countries outside of South Korea. This collaborative research project is focusing on evaluating new technology to diagnose the drug susceptibility of clinical isolates of Mycobacterium tuberculosis and identify the pathogenic features influence the treatment outcomes of pulmonary tuberculosis.
2. Project Details
2.1. Title
Evaluation the efficacy of the prototype NGS-based drug susceptibility test kit and study on the influence of genetic traits of prevalent Mycobacterium tuberculosis strain on treatment outcome in tuberculosis-high burden country
2.2. Project Period
From start date in 2023(mm/dd/2023) for 12 month
2.3. Funding
100,000,000 KRW
2.4 Countries
TB-high burden countries in Asia (more than 20/100,000 people in TB incidence)
2.5. Eligibility of Applicants
Must have a Ph.D. or an MD.
2.6. Research Areas of Focus and Required methods
2.6.1. Evaluation the efficacy of the prototype MDR-TB detection kit developed by KNIH
- Collecting sputum samples from newly diagnosed TB patients
- Targeted sequencing by next generation sequencing methods
- Phenotypic drug susceptibility test
2.6.2. Study on the influence of genetic traits of prevalent Mtb stain in TB-high burden country on treatment outcomes
- Analysis clinical isolates of Mtb with whole genome sequencing to identify the genetic features
- Analysis the clinical information including treatment outcome of the TB patients from whom clinical Mycobacterium tuberculosis strains were isolated to reveal the influence of genetic trait of Mycobacterium tuberculosis on treatment response and outcome
3. Affiliation
Government institute, university, hospital, etc.
4. Key Dates and Reporting System
4.1. Application open date
- Oct. 31, 2023
4.2. Letter of Intent (LOI) & application due date
- Nov.6, 2023
* The LOI and the project proposal should be submitted via e-mail(whitevet81@korea.kr)
A reply confirming your successful submission will be e-mailed in three days.
* Format of documents should be MS Word in English.
4.3. Result notification (via e-mail)
- Nov. 13, 2023
5. Contact
whitevet81@korea.kr
(28159) 187, Osongsaengmyeong2-ro, Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do,
Division of Bacterial Disease Research,
Center for Infectious Disease Research, National Institute of Health, Korea Disease Control and Prevention Agency, South Korea
TEL: +82-43-719-8477
FAX: +82-43-719-8489
Download